Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Batten disease (neuronal ceroid lipofuscinoses), including CLN2 disease: US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Batten disease (CLN2): the short answer

The US FDA has approved one medicine covered on this page for Batten disease (CLN2), each for a specific group of patients: Brineura. On 17 October 2026, one of them was on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Brineura.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital; cell and gene therapies at a qualified center.
  • Price: Quote on request.

What is Batten disease (CLN2)?

Batten disease is the common name for a group of inherited disorders called neuronal ceroid lipofuscinoses (NCLs). In these disorders, waste material builds up in nerve cells and other cells, leading to seizures, loss of vision, and loss of movement and thinking skills over time.[1]

CLN2 disease is one form. It usually begins with seizures between ages 2 and 4, followed by loss of speech, walking and vision. It is caused by changes in the TPP1 gene and is inherited in an autosomal recessive pattern. More than 300 cases have been described worldwide.[2]

CLN3 is the most common form of Batten disease.[1]

Batten disease (CLN2) in the Gulf

Neuronal ceroid lipofuscinoses have been studied in the Gulf, including a 2024 study of clinical and molecular characteristics in Saudi Arabia, a report of late-infantile CLN2 disease in Oman, and a report from Qatar of a novel CLN5 mutation in the Arab population.[3, 4, 5]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 0 of 1 were listed in Saudi Arabia and 1 of 1 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[6, 7]

US FDA-approved medicines for Batten disease (CLN2)

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Brineura (cerliponase alfa)
    US FDA-approved for slowing the loss of walking ability in children with CLN2 disease (TPP1 deficiency). It is an enzyme given every other week into the fluid around the brain through a surgically placed device, at a specialized center.[8]
    Current US label version: 5 August 2024. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[9, 10] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

For Brineura. These are made for one patient or given through a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center that can give the treatment, which may be abroad. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for Batten disease (CLN2)

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for Batten disease (CLN2)?

Yes. The medicine on this page has US FDA approval for specific groups of patients: Brineura. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Brineura available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Brineura?

It is given at a qualified center. Your specialist refers the patient, the center checks eligibility, and the family plans funding and travel. A local hospital can only give it if the manufacturer agrees to supply it and the regulator approves.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Does Brineura work for all types of Batten disease?

No. Brineura's US label is for CLN2 disease (TPP1 deficiency) only. Genetic or enzyme testing confirms the type.

Sources for the condition-specific answers: [8]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. National Institute of Neurological Disorders and Stroke (NINDS): Batten Disease (Neuronal Ceroid Lipofuscinosis)
  2. MedlinePlus Genetics (US National Library of Medicine): CLN2 disease
  3. Saleh MM, et al. Clinical and Molecular Characteristics of Neuronal Ceroid Lipofuscinosis in Saudi Arabia. Pediatr Neurol. 2024 (PubMed 38653183)
  4. Koul R, et al. Late-infantile neuronal ceroid lipofuscinosis (CLN2/Jansky-Bielschowsky type) in Oman. J Child Neurol. 2007 (PubMed 17690061)
  5. Al-Kowari MK, et al. Neuronal ceroid lipofuscinosis in Qatar: report of a novel mutation in ceroid-lipofuscinosis, neuronal 5 in the Arab population. J Child Neurol. 2011 (PubMed 21447811)
  6. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  7. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  8. DailyMed: BRINEURA (cerliponase alfa) US prescribing information, label version 5 August 2024
  9. SFDA: Special Access Program (SAP) guidance, version 1.0
  10. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp